Abstract
Etoposide is an antineoplastic agent widely used for treatment of many
pediatric cancers and associated with infusion related adverse drug
reactions (ADRs). In this brief report we describe etoposide infusion
related ADRs that occurred over a 10-year period at two freestanding
pediatric hospitals. Infusion reactions occurred in 1% of patients. Of
the 32 patients that experienced adverse reactions, 41% were
rechallenged after the reaction and all were able to tolerate at least
one future dose with either pre-treatment or extending infusion
duration.